News for CRISPR Therapeutics AG (0VRQ.L)

On Monday, Cathie Wood-led Ark Invest made significant trades, including a notable purchase of Bitmine Immersion Technologies Inc. (BMNR) shares.

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $66.06, moving 3.05% from the previous trading session.

Significant Transaction by BlackRock, Inc. (Trades, Portfolio) On June 30, 2025, BlackRock, Inc. (Trades, Portfolio) executed a noteworthy transaction by acquir

Crispr Therapeutics AG stock has soared 90% since May, driven by Casgevy approval and future breakthroughs in gene editing. Click for my CRSP stock update.

On July 22, 2025, B of A Securities released an updated analyst report on CRISPR Therapeutics (CRSP). The report, issued by analyst Geoff Meacham, highlights a

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Bank of America has revised its target price for Crispr Therapeutics (CRSP) from $79 to $78, maintaining a Buy rating on the stock. The adjustment comes as the

We recently published These 10 Stocks Surprisingly Lead Gains While Wall Street Naps. CRISPR Therapeutics AG (NASDAQ:CRSP) is one of this week’s top performers. CRISPR Therapeutics soared by 18.22 percent on Friday to close at $65.13 apiece to hit a new all-time high as investors took path from a recent insider trading that gobbled up shares worth […]

U.S. stocks finished mixed on Friday, July 18, 2025, as investors digested fresh economic data and positioned themselves ahead of next week's highly

Crispr Therapeutics (CRSP) experienced a significant surge, with its shares climbing 16.4%, or $9.06, reaching a price of $64.15. This notable increase in the s

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $52.73, denoting a -6.54% move from the preceding trading day.

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Summary On July 9, 2025, CRISPR Therapeutics AG (CRSP) announced significant progress in its in vivo cardiovascular disease programs. The company provided updat

PR NewswireNEW YORK, July 9, 2025 NetworkNewsWire Editorial CoverageNEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are d

Today, ARK Investment Management, led by Cathie Wood, expanded its holdings by purchasing 103,000 shares of Crispr Therapeutics (CRSP). This move reflects the f

Cathie Wood's Ark Investment Management has filed plans to launch four new exchange-traded funds designed to offer downside protection for investors in its flagship ARK Innovation ETF (BATS: ARKK), while placing a cap on potential gains.

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $51.19, representing a -1.88% change from its previous close.

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.